GSA Capital Partners LLP Increases Position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

GSA Capital Partners LLP lifted its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 656.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 88,911 shares of the biotechnology company's stock after buying an additional 77,153 shares during the quarter. GSA Capital Partners LLP owned approximately 0.07% of Aurinia Pharmaceuticals worth $715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Federated Hermes Inc. grew its position in Aurinia Pharmaceuticals by 35.7% in the 1st quarter. Federated Hermes Inc. now owns 66,988 shares of the biotechnology company's stock valued at $539,000 after acquiring an additional 17,629 shares during the last quarter. Mackenzie Financial Corp purchased a new position in Aurinia Pharmaceuticals in the 1st quarter worth about $86,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Aurinia Pharmaceuticals by 24.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,641 shares of the biotechnology company's stock valued at $343,000 after buying an additional 8,390 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth about $140,000. Finally, IFP Advisors Inc grew its stake in Aurinia Pharmaceuticals by 2.4% in the 1st quarter. IFP Advisors Inc now owns 277,580 shares of the biotechnology company's stock worth $2,232,000 after acquiring an additional 6,448 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $10.49 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93. The company has a 50 day moving average price of $8.35 and a 200-day moving average price of $8.13. Aurinia Pharmaceuticals Inc has a fifty-two week low of $5.20 and a fifty-two week high of $10.67. The stock has a market capitalization of $1.42 billion, a PE ratio of 24.40 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 19.57% and a net margin of 23.31%. Equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AUPH. HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada increased their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.